Market closed
Atea/$AVIR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Atea
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
Ticker
$AVIR
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
56
Website
Atea Metrics
BasicAdvanced
$232M
-
-$2.00
0.17
-
Price and volume
Market cap
$232M
Beta
0.17
52-week high
$4.14
52-week low
$2.60
Average daily volume
423K
Financial strength
Current ratio
24.854
Quick ratio
24.443
Long term debt to equity
0.192
Total debt to equity
0.374
Management effectiveness
Return on assets (TTM)
-22.76%
Return on equity (TTM)
-33.88%
Valuation
Price to book
0.52
Price to tangible book (TTM)
0.52
Price to free cash flow (TTM)
-1.685
Growth
Earnings per share change (TTM)
22.57%
3-year earnings per share growth (CAGR)
13.41%
What the Analysts think about Atea
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Atea stock.
Atea Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Atea Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Atea News
AllArticlesVideos
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
GlobeNewsWire·2 weeks ago
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
GlobeNewsWire·3 weeks ago
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Atea stock?
Atea (AVIR) has a market cap of $232M as of May 09, 2025.
What is the P/E ratio for Atea stock?
The price to earnings (P/E) ratio for Atea (AVIR) stock is 0 as of May 09, 2025.
Does Atea stock pay dividends?
No, Atea (AVIR) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Atea dividend payment date?
Atea (AVIR) stock does not pay dividends to its shareholders.
What is the beta indicator for Atea?
Atea (AVIR) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.